Financial Performance - Total revenue for the reporting period was ¥63,350,551.55, down 5.82% year-over-year[9]. - Net profit attributable to shareholders was ¥2,564,989.42, a decline of 25.37% compared to the same period last year[9]. - Basic earnings per share were ¥0.0189, down 25.30% year-over-year[9]. - The weighted average return on equity decreased to 0.66%, down 0.31 percentage points from the previous year[9]. - The company reported a total operating cost of ¥196,603,073.90 for the year-to-date period, a decrease from ¥200,408,821.86[73]. - Year-to-date net profit was ¥20,797,886.24, compared to ¥23,778,540.85, indicating a decrease of approximately 12.5%[74]. - The company's total revenue for Q3 2014 was ¥59,963,459.55, an increase from ¥53,166,792.07 in the previous period[69]. - Net profit for Q3 2014 was ¥5,149,562.58, down from ¥5,729,300.36, indicating a decrease of about 10.1% year-over-year[69]. Assets and Liabilities - Total assets at the end of the reporting period were ¥523,954,659.29, a decrease of 7.37% compared to the previous year[9]. - Cash and cash equivalents decreased by 76.03%, from 170,129,083.93 to 40,779,894.86, primarily due to increased bank loan repayments and cash outflows from operating activities[24]. - Accounts receivable increased by 261.31%, from 794,000.00 to 2,868,796.22, mainly due to an increase in customers using bank acceptance bills for settlement[24]. - Inventory increased by 56.34%, from 33,455,933.68 to 52,306,556.21, attributed to an increase in unfinished projects at the end of the period[24]. - Total liabilities decreased to ¥118,735,579.20 from ¥170,449,151.64, indicating a significant reduction in financial obligations[61]. Strategic Initiatives - The company is focusing on expanding into smart healthcare and smart city sectors as part of its strategic transformation[12]. - The company plans to enhance R&D efforts to quickly launch new products that meet market demands[12]. - The company is actively pursuing technology R&D, market expansion, and mergers and acquisitions to drive business transformation[27]. - Significant projects include the successful signing of the "Digital Hospital Construction" project with Guiyang Fourth People's Hospital and the establishment of a joint R&D center with Fuwai Hospital[27]. - The company is developing a comprehensive health service platform to address the rapid growth of health big data and improve grassroots medical service levels[30]. Market Presence and Competition - The company is actively expanding its market presence beyond Northeast China to mitigate regional concentration risks[14]. - The company faces intensified competition in the IT service sector, which may impact future profitability and operational performance[38]. - The overall business performance remains stable despite increased operational costs and intensified market competition[27]. Financial Management - The management is committed to strengthening accounts receivable management to address potential cash flow impacts[15]. - The company received tax refunds of 4,935,860.45, a 162.86% increase compared to the previous year, due to increased VAT refunds[26]. - Financial expenses rose by 222.97%, from 888,499.73 to 2,869,628.31, mainly due to increased interest expenses[25]. - The company is focused on improving accounts receivable management to address potential cash flow impacts from increased receivables[40]. Shareholder Information - Total number of shareholders at the end of the reporting period is 6,635[18]. - The top two shareholders, Fu Yanjie and Cui Wantao, each hold 28.87% of the shares, totaling 39,266,714 shares, which are pledged[18]. - The total number of restricted shares at the end of the period is 79,012,400, with no new restricted shares added during the reporting period[21]. Cash Flow and Investments - Cash inflow from sales of goods and services reached ¥190,271,078.45, an increase from ¥167,208,810.77 in the previous period[79]. - Total cash inflow from operating activities amounted to ¥206,030,012.98, compared to ¥178,039,223.27 in the prior period, reflecting a growth of approximately 15%[80]. - The company has achieved a cumulative investment of CNY 10,759.83 million against a committed investment of CNY 12,870.16 million[46]. - The company distributed a cash dividend of CNY 0.80 per share, totaling CNY 10.88 million, based on a total share capital of 136 million shares as of December 31, 2013[53].

Financial Performance - Total revenue for the reporting period was ¥150,314,156.01, a decrease of 3.64% compared to ¥155,992,877.72 in the same period last year[18]. - Net profit attributable to ordinary shareholders was ¥18,760,891.18, down 7.98% from ¥20,387,281.07 year-on-year[18]. - Basic earnings per share decreased by 8.01% to ¥0.1379 from ¥0.1499 in the same period last year[18]. - The weighted average return on net assets decreased to 4.74%, down 1.02 percentage points from 5.76% in the previous year[18]. - The company achieved operating revenue of 150.31 million yuan, a decrease of 3.64% compared to the same period last year[28]. - Net profit attributable to shareholders was 18.76 million yuan, down 7.98% year-on-year[28]. - The company reported a net profit of ¥18,760,891.18 for the current period, contributing to an increase in retained earnings[130]. - The total equity attributable to the parent company at the end of the period was ¥402,888,867.58, reflecting a slight increase from the previous year[131]. Cash Flow and Liquidity - Net cash flow from operating activities improved to -¥54,456,255.36, a 66.84% increase compared to -¥164,203,923.66 in the previous year[18]. - The cash inflow from operating activities was ¥151,795,166.52, an increase from ¥135,122,915.15 in the previous period, suggesting better operational performance[128]. - The net cash flow from operating activities was -¥38,953,487.27, an improvement from -¥151,154,899.84 in the previous period, indicating a significant reduction in cash outflow[128]. - Cash and cash equivalents decreased from 170,129,083.93 RMB to 90,684,309.77 RMB, representing a decline of about 46.6%[109]. - The total cash and cash equivalents at the end of the period stood at ¥79,823,385.38, down from ¥103,451,376.94 at the end of the previous period[129]. Investment and R&D - Research and development investment increased by 7.95% to 11.46 million yuan[29]. - The company plans to enhance research and development efforts in the livelihood sector to meet evolving customer needs and explore new profit growth points[24]. - The company is continuing its unified development platform project based on J2EE 5 architecture, aiming for productization[41]. - The organic solar cell research project focuses on high-performance inverted molecular solar cell technology as part of the company's foundational research investment[41]. - The company has made significant progress in developing medical big data platforms, particularly in personal health management[46]. Market Strategy and Business Development - The company plans to focus on innovation and service improvement to address the slowdown in client demand due to macroeconomic conditions[24]. - The strategic shift towards smart healthcare and smart city projects is aimed at expanding the market and mitigating operational risks associated with business structure adjustments[24]. - The company focused on smart healthcare and smart city projects, achieving significant breakthroughs in market expansion[28]. - The company plans to continue its strategic focus on mergers and acquisitions to expand its market reach beyond the northeastern region[28]. - The company has established a technology competitiveness in smart city solutions, including intelligent video analysis and big data analytics[45]. Financial Position and Assets - Total assets at the end of the reporting period were ¥530,931,075.44, a decline of 6.13% from ¥565,615,807.03 at the end of the previous year[18]. - The total amount of raised funds is 188.87 million RMB, with 12.53 million RMB already invested during the reporting period[50]. - The cumulative amount of raised funds invested to date is 125.29 million RMB[50]. - The company reported a total of 436,947,788.06 RMB in current assets at the end of the reporting period, down from 476,077,459.34 RMB at the beginning of the period, indicating a decrease of approximately 8.6%[109]. - The total equity at the end of the current period is CNY 390,834,195.11, up from CNY 343,184,726.17 at the end of the previous year, indicating a growth of approximately 13.9%[138]. Shareholder Information - The total number of shareholders at the end of the reporting period is 8,986[95]. - The company has 136,000,000 shares in total, with 79,012,400 shares (58.10%) under limited sale conditions and 56,987,600 shares (41.90%) under unrestricted sale conditions[95]. - The company distributed a cash dividend of 0.80 RMB per share, totaling 10.88 million RMB, based on a total share capital of 136 million shares as of December 31, 2013[63]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[66]. Compliance and Governance - The company adheres to the Chinese Accounting Standards, ensuring that its financial statements accurately reflect its financial position and operating results as of June 30, 2014[148]. - The company has a structured governance framework with a board of directors consisting of 9 members, including 3 independent directors, and a supervisory board with 3 members[146]. - There were no significant litigation or arbitration matters during the reporting period[69]. - The company did not engage in any related party transactions during the reporting period[74]. Accounting Policies and Practices - The company’s accounting policies include specific methods for handling mergers and acquisitions, ensuring compliance with relevant accounting standards[153][155]. - Cash and cash equivalents are defined as cash on hand and deposits that are readily available for payment, with cash equivalents typically maturing within three months from the date of purchase[160]. - The company applies an aging analysis method for receivables, with specific percentages for impairment provisions based on aging categories, such as 2% for within 1 year and 100% for over 5 years[177]. - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recognized when costs exceed net realizable values[180].

2014 年 04 月 2014 年第一季度报告全文 荣科科技股份有限公司 Bringspring Science and Technology Co.,Ltd. 2014 年第一季度报告 1 2014 年第一季度报告全文 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资 料不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准 确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人付永全、主管会计工作负责人冯丽及会计机构负责人(会计主管 人员)朱迎秋声明：保证季度报告中财务报告的真实、完整。 2 2014 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业总收入（元） | 64,508,854.25 | 46,997,295.35 | 37.26% | | 归属于公司普通股 ...

Financial Performance - The company's operating revenue for 2013 was CNY 375,586,047.92, representing a 12.20% increase compared to CNY 334,734,262.56 in 2012[26] - The net profit attributable to shareholders of the listed company was CNY 53,211,289.80, an increase of 6.72% from CNY 49,862,341.25 in the previous year[26] - The total assets at the end of 2013 amounted to CNY 565,615,807.03, reflecting an 11.51% increase from CNY 507,253,746.40 at the end of 2012[26] - The company's cash flow from operating activities was negative at CNY -113,996,084.75, a significant decline of 471.32% compared to CNY 30,700,578.99 in 2012[26] - The basic earnings per share for 2013 was CNY 0.3913, a 2.27% increase from CNY 0.3826 in 2012[26] - The weighted average return on equity decreased to 14.58%, down by 2.07 percentage points from 16.65% in the previous year[26] - The total liabilities at the end of 2013 were CNY 170,449,151.64, which is a 5.05% increase from CNY 162,248,506.90 at the end of 2012[26] - The company's asset-liability ratio improved to 30.14%, a decrease of 1.85 percentage points from 31.99% in 2012[26] - The net profit after deducting non-recurring gains and losses was CNY 47,168,700.22, up 4.53% from CNY 45,122,553.86 in 2012[26] Investment and R&D - The company invested CNY 25,912,875.73 in R&D in 2013, representing 6.90% of its operating revenue[61] - The R&D investment increased from CNY 16,566,993.48 in 2012 to CNY 25,912,875.73 in 2013, showing a growth rate of approximately 56.4%[61] - Significant investments in technology innovation and product development have been made, focusing on smart city and smart healthcare solutions, with new systems and platforms being developed[44] - The company completed the development of multiple new products, including a mobile medical information management system and a social security risk supervision platform[60] - The company is in the research phase for a low-power wearable ECG measurement device, indicating a focus on innovative health technology[61] Market Expansion and Strategy - The company is actively expanding into international markets, particularly in the Northwest, North China, and Southwest regions, while also pursuing overseas acquisitions to enhance its presence in the U.S. market[43] - The company aims to enhance its core technological competitiveness in the smart city sector, focusing on video, image analysis, GIS, and expert decision systems[103] - The company is actively pursuing market expansion through new product development and strategic partnerships in the healthcare sector[60] - The company plans to establish multiple customer joint innovation bases to develop leading domestic solutions in smart healthcare and smart cities[103] Financial Management and Structure - The company has optimized its business structure by integrating IoT, cloud computing, and mobile internet technologies into existing products, enhancing profitability[47] - The company has emphasized strengthening internal control systems to ensure effective risk management and compliance[50] - The company has committed to investing in projects totaling approximately $12.87 million, with a significant portion of raised funds already allocated[83] - The company has utilized 600.00 million of the raised funds to permanently supplement working capital, which is limited to operations related to its main business[87] Shareholder and Equity Information - The total number of shares increased from 68,000,000 to 136,000,000 due to a capital reserve conversion of 10 shares for every 10 shares held[162] - The proportion of limited sale shares decreased from 75.00% to 58.10% after the release of certain pre-IPO restricted shares[161] - The number of unrestricted shares increased from 17,000,000 to 56,980,648, representing 41.90% of the total shares[161] - The company had a total of 9,414 shareholders at the end of the reporting period, an increase from 9,179 in the previous period[170] - Major shareholders, Fu Yanjie and Cui Wantao, each hold 28.87% of the shares, totaling 39,266,714 shares[170] Risk Factors - The company faces risks related to market competition, seasonal fluctuations, and human resource challenges, which could impact its operational performance[36][37][38] - Fixed asset depreciation is expected to increase due to ongoing investment projects, potentially leading to a decline in profits[39] Corporate Governance - The company has established an insider information management system to protect investors' rights and ensure fair information disclosure[121] - The company has not faced any penalties from securities regulatory authorities for its directors, supervisors, or senior management[195] - The company’s board of directors includes independent members with academic and professional backgrounds in economics and finance[190] Compensation and Remuneration - Total compensation for the company's directors and senior management during the reporting period amounted to 358 million[198] - The chairman and general manager, Fu Yongquan, received a total compensation of 74 million[198] - The financial director, Feng Li, received a total compensation of 52 million[198] - The sales director, Yin Chunfu, received a total compensation of 55 million[198]